- GH Research Ireland Ltd, a Dublin, Ireland-based clinical-stage biopharmaceutical company, closed a $125m Series B financing
- The round co-led by RA Capital and RTW Investments, LP, with participation from existing investor BVF Partners
- Founded in 2018, GH Research Ireland also develops novel therapies for the management of psychiatric and neurological disorders
- The company’s lead product, GH001, is an innovative drug product for 5-MeO-DMT administration via a proprietary inhalation approach
- The company’s goal is to administer GH001 in a single-day individualized dosing regimen that enables patients to achieve a rapid and durable remission with convenient administration
- GH Research Ireland plans to advance GH001 into clinical development in additional psychiatric and neurological disorders beyond Treatment-Resistant Depression
